Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIBERA: Bevacizumab vs Ranibizumab in AMD
NCT00559715Phase 3Unknown
- Sponsor
- Klinikum Bremen-Mitte
- Start
- Aug 2008
- Primary completion
- Aug 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of bevacizumab in exudative macular degeneration, sponsored by Klinikum Bremen-Mitte. Status: unknown.
02
Drugs
bevacizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT00559715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00559715.